AI
Monday, March 14, 2011 7:17:00 PM
Teva President and CEO Shlomo Yanai said last week after presenting second-quarter results that he had good reason to believe his company was close to getting approval for its generic version of Lovenox, but he gave no timeline.
How can that be? A reliable source has told us that TEVA gave up saying that tL was close to approval.
ij
There are times when rules and precedents cannot be broken; others when they cannot be adhered to with safety. (Thomas Joplin)
Trade Smarter with Thousands
Leverage decades of market experience shared openly.
